Xinyuan Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinyuan Qiao has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Lijie Tang
College of Veterinary Medicine, Northeast Agricultural University
16 shared publications - Yijing Li
College of Veterinary Medicine, Northeast Agricultural University
15 shared publications - Li Wang
College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
14 shared publications - Wen Cui
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China
13 shared publications - Xiaona Wang
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China
12 shared publications Wen Cui
Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Department of Preventive Veterinary, College of Veterinary, Northeast Agricultural University
11 shared publications
Latest Publications
- Open Access
A High-Potency Bovine Consensus Interferon Delivered by an Oral Lactococcus lactis System Exhibits Antiviral Activity Against VSV and BEV
Interferon-alpha (IFN-α) mediates innate antiviral immunity. Although it comprises multiple subtypes, their functional divergence and application potential remain incompletely characterized. In this study, we identified 13 BoIFN-α subtypes (A1–A13) in the bovine genome through bioinformatic analysis. Prokaryotic expression and functional comparison revealed substantial differences in antiviral activity among these subtypes (up to 77.7-fold), with BoIFN-A8 being the most potent. Based on these findings, we designed a novel consensus interferon, BoIFN-Acons, by multiple sequence alignment and successfully synthesized it. When expressed in E. coli, BoIFN-Acons exhibited superior antiviral potency (2.36 × 105 U/mg), which was 16.2-fold higher than that of the most active natural subtype. To establish a safe delivery system, we integrated the codon-optimized gene into a food-grade L. lactis expression platform and achieved efficient supernatant production. In vitro assays confirmed that the recombinant BoIFN-Acons effectively suppressed replication of Vesicular stomatitis virus (VSV) and Bovine enterovirus (BEV) and significantly upregulated interferon-stimulated genes (ISGs) such as Mx1 and OAS1. Furthermore, in vivo experiments demonstrated that oral administration of the engineered L. lactis strain alleviated virus-induced clinical symptoms, reduced viral loads in major tissues, and induced upregulation of immune-related genes in the spleen, showing significant prophylactic and therapeutic efficacy. Collectively, this study systematically elucidated the functional diversity of BoIFN-α subtypes and developed a highly active consensus interferon delivered via an oral lactic acid bacteria system, providing a new strategy for the eco-friendly control of animal viral diseases.
Open AccessA High-Potency Bovine Consensus Interferon Delivered by an Oral Lactococcus lactis System Exhibits Antiviral Activity Against VSV and BEV
Interferon-alpha (IFN-α) mediates innate antiviral immunity. Although it comprises multiple subtypes, their functional divergence and application potential remain incompletely characterized. In this study, we identified 13 BoIFN-α subtypes (A1–A13) in the bovine genome through bioinformatic analysis. Prokaryotic expression and functional comparison revealed substantial differences in antiviral activity among these subtypes (up to 77.7-fold), with BoIFN-A8 being the most potent. Based on these findings, we designed a novel consensus interferon, BoIFN-Acons, by multiple sequence alignment and successfully synthesized it. When expressed in E. coli, BoIFN-Acons exhibited superior antiviral potency (2.36 × 105 U/mg), which was 16.2-fold higher than that of the most active natural subtype. To establish a safe delivery system, we integrated the codon-optimized gene into a food-grade L. lactis expression platform and achieved efficient supernatant production. In vitro assays confirmed that the recombinant BoIFN-Acons effectively suppressed replication of Vesicular stomatitis virus (VSV) and Bovine enterovirus (BEV) and significantly upregulated interferon-stimulated genes (ISGs) such as Mx1 and OAS1. Furthermore, in vivo experiments demonstrated that oral administration of the engineered L. lactis strain alleviated virus-induced clinical symptoms, reduced viral loads in major tissues, and induced upregulation of immune-related genes in the spleen, showing significant prophylactic and therapeutic efficacy. Collectively, this study systematically elucidated the functional diversity of BoIFN-α subtypes and developed a highly active consensus interferon delivered via an oral lactic acid bacteria system, providing a new strategy for the eco-friendly control of animal viral diseases.
- Open Access
- 23 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1606
Prophylactic Administration of Engineered Bacillus subtilis Expressing Mucosal Repair Factors Alleviates Pullorum Disease in Chicks
Salmonella pullorum (S. pullorum) remains a major enteric pathogen in young chicks, causing high mortality and severe economic losses in poultry production. This study evaluated a prophylactic strategy using engineered Bacillus subtilis (B. subtilis) expressing gallus trefoil factor 2 (gTFF2) and epidermal growth factor (gEGF) to protect chicks against S. pullorum infection. In vitro, gEGF significantly promoted UMNSAH/DF-1 (DF-1) cell proliferation, whereas both gTFF2 and gEGF enhanced epithelial cell migration. In vivo, oral administration of recombinant B. subtilis significantly reduced mortality from 75.0% and 66.7% in the PBS and pHT43 groups to 50%, 33.3%, and 25.0% in the gTFF2, gEGF, and gTFF2+gEGF groups, respectively. Cecal colonization of S. pullorum was reduced by 2–4 log10 CFU/g, accompanied by improved average daily gain and immune organ indices. Treatment also significantly decreased serum IL-6 levels and increased TGF-β levels (p < 0.05), indicating attenuation of the inflammatory response. Histological analysis showed significantly increased villus height (0.94–1.58-fold) and villus height-to-crypt depth ratio (1.47–3.25-fold) compared with the infected controls, together with markedly alleviated hepatic and intestinal lesions. The combined administration of gTFF2- and gEGF-expressing strains consistently exhibited the greatest protective efficacy. Collectively, these findings demonstrate that engineered probiotic-mediated delivery of mucosal repair factors represents a promising antibiotic-alternative strategy for preventing pullorum disease and improving intestinal health in poultry production.
- 23 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1606
Open AccessProphylactic Administration of Engineered Bacillus subtilis Expressing Mucosal Repair Factors Alleviates Pullorum Disease in Chicks
Salmonella pullorum (S. pullorum) remains a major enteric pathogen in young chicks, causing high mortality and severe economic losses in poultry production. This study evaluated a prophylactic strategy using engineered Bacillus subtilis (B. subtilis) expressing gallus trefoil factor 2 (gTFF2) and epidermal growth factor (gEGF) to protect chicks against S. pullorum infection. In vitro, gEGF significantly promoted UMNSAH/DF-1 (DF-1) cell proliferation, whereas both gTFF2 and gEGF enhanced epithelial cell migration. In vivo, oral administration of recombinant B. subtilis significantly reduced mortality from 75.0% and 66.7% in the PBS and pHT43 groups to 50%, 33.3%, and 25.0% in the gTFF2, gEGF, and gTFF2+gEGF groups, respectively. Cecal colonization of S. pullorum was reduced by 2–4 log10 CFU/g, accompanied by improved average daily gain and immune organ indices. Treatment also significantly decreased serum IL-6 levels and increased TGF-β levels (p < 0.05), indicating attenuation of the inflammatory response. Histological analysis showed significantly increased villus height (0.94–1.58-fold) and villus height-to-crypt depth ratio (1.47–3.25-fold) compared with the infected controls, together with markedly alleviated hepatic and intestinal lesions. The combined administration of gTFF2- and gEGF-expressing strains consistently exhibited the greatest protective efficacy. Collectively, these findings demonstrate that engineered probiotic-mediated delivery of mucosal repair factors represents a promising antibiotic-alternative strategy for preventing pullorum disease and improving intestinal health in poultry production.
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1839510
Lactobacillus casei bacterial ghost-based DNA vaccine enhances the immune protection effect by stimulating macrophages to regulate intestinal mucosal immunity
Porcine rotavirus is a major threat to the swine industry, yet effective vaccines are still lacking. Lactobacillus casei bacterial ghosts ( L. casei BGs) as DNA vaccine delivery vehicles represent a promising approach, providing a safe and structurally intact platform that enhances antigen presentation and elicits intestinal mucosal immunity. To elucidate how L. casei BGs regulate macrophage function and amplify mucosal immune responses, we investigated the response of macrophages and the intestinal mucosal immune system to an L. casei BG-based DNA vaccine encoding VP7. Using genetically engineered L. casei BGs, we performed in vitro macrophage stimulation and in vivo oral/intramuscular immunization in murine models, assessing phagocytic efficiency, TLR/MyD88/NF-κB pathway activation, M1 polarization, antigen presentation, serum IgG, fecal IgA, T cell proliferation, intestinal viral load, virus neutralization, and intestinal histopathology. Compared with a naked DNA vaccine, the L. casei BG-based vaccine significantly enhanced phagocytosis and antigen presentation and promoted M1 polarization via the TLR/MyD88/NF-κB pathway. Furthermore, oral administration of the vaccine proved superior to intramuscular injection in inducing mucosal immunity, preserving intestinal villus integrity, and enhancing antiviral protection. Collectively, this study establishes L. casei BGs as an effective DNA vaccine delivery system that enhances immunogenicity by modulating macrophage function and activating mucosal immunity, and offers a promising strategy for the control of porcine rotavirus infection.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1839510
Open AccessLactobacillus casei bacterial ghost-based DNA vaccine enhances the immune protection effect by stimulating macrophages to regulate intestinal mucosal immunity
Porcine rotavirus is a major threat to the swine industry, yet effective vaccines are still lacking. Lactobacillus casei bacterial ghosts ( L. casei BGs) as DNA vaccine delivery vehicles represent a promising approach, providing a safe and structurally intact platform that enhances antigen presentation and elicits intestinal mucosal immunity. To elucidate how L. casei BGs regulate macrophage function and amplify mucosal immune responses, we investigated the response of macrophages and the intestinal mucosal immune system to an L. casei BG-based DNA vaccine encoding VP7. Using genetically engineered L. casei BGs, we performed in vitro macrophage stimulation and in vivo oral/intramuscular immunization in murine models, assessing phagocytic efficiency, TLR/MyD88/NF-κB pathway activation, M1 polarization, antigen presentation, serum IgG, fecal IgA, T cell proliferation, intestinal viral load, virus neutralization, and intestinal histopathology. Compared with a naked DNA vaccine, the L. casei BG-based vaccine significantly enhanced phagocytosis and antigen presentation and promoted M1 polarization via the TLR/MyD88/NF-κB pathway. Furthermore, oral administration of the vaccine proved superior to intramuscular injection in inducing mucosal immunity, preserving intestinal villus integrity, and enhancing antiviral protection. Collectively, this study establishes L. casei BGs as an effective DNA vaccine delivery system that enhances immunogenicity by modulating macrophage function and activating mucosal immunity, and offers a promising strategy for the control of porcine rotavirus infection.
- Open Access
- 5 June 2026
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1) , 331
Correction: Distribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China
- 5 June 2026
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1) , 331
Open AccessCorrection: Distribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China
- 23 April 2026
- Published by Elsevier in Research in Veterinary Science
- Vol. 207, 106223
Untargeted metabolomics reveals bovine viral diarrhea virus infection reprogram host nucleotide and amino acid metabolism in MDBK Cells
- 23 April 2026
- Published by Elsevier in Research in Veterinary Science
- Vol. 207, 106223
Untargeted metabolomics reveals bovine viral diarrhea virus infection reprogram host nucleotide and amino acid metabolism in MDBK Cells
- 20 April 2026
- Published by Elsevier in Veterinary Microbiology
- Vol. 318, 111036
Phage therapy: A novel strategy to combat drug-resistant Salmonella Pullorum infection in chickens
- 20 April 2026
- Published by Elsevier in Veterinary Microbiology
- Vol. 318, 111036
Phage therapy: A novel strategy to combat drug-resistant Salmonella Pullorum infection in chickens
- Open Access
- 12 December 2025
- Published by Elsevier in Poultry Science
- Vol. 105 (2) , 106273
Biological functional identification of holins from Salmonella pullorum phages and their therapeutic efficacy against pullorum disease in chickens
- 12 December 2025
- Published by Elsevier in Poultry Science
- Vol. 105 (2) , 106273
Open AccessBiological functional identification of holins from Salmonella pullorum phages and their therapeutic efficacy against pullorum disease in chickens
- Open Access
- 10 December 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1)
Distribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China
The spread of drug-resistant Staphylococcus aureus(S.aureus) in cattle herds not only threatens livestock production but also becomes an important route fo
- 10 December 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1)
Open AccessDistribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China
The spread of drug-resistant Staphylococcus aureus(S.aureus) in cattle herds not only threatens livestock production but also becomes an important route fo
- Open Access
- 25 February 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1499566
Biological function identification of phage holin Hol-4086 and treatment of Staphylococcus aureus infection
The treatment of infections caused by drug-resistant Staphylococcus aureus has become increasingly difficult. In this study, the complete genome of phage 4086-1 against S. aureus was sequenced and shown to be 17,960 bp in size, with a GC content of 29.14%. Phylogenetic analysis demonstrated that phage 4086-1 exhibited a close relationship with the Staphylococcus phages SLPW, JPL-50, and LSA2366. BLAST analysis indicated that ORF12 of phage 4086-1 (termed Hol-4086) shares high identity with other reported phage-associated holins. Hol-4086 consists of 140 amino acids and exhibits high sequence identity with some members of the phage_holin_4_1 superfamily (18–125 amino acids). Hol-4086 was then expressed in Escherichia coli and detected using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting. The results of a spot test demonstrated that Hol-4086 had substantial bacteriostatic effects on the host bacteria. S. aureus cells were exposed to Hol-4086 and observed using transmission electron microscopy and scanning electron microscopy. Bacterial cells treated with Hol-4086 showed ultrastructural and morphological changes. The detection of biofilm activity showed that Hol-4086 effectively inhibited and removed S. aureus biofilms. In vivo, treatment with Hol-4086 significantly reduced the number of bacteria, relieved inflammatory responses, and alleviated pathological changes in the organs of infected mice 48 h after treatment. These results demonstrate that Hol-4086 exhibits promising antibacterial potential as an alternative therapy for the treatment of infections caused by S. aureus.
- 25 February 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1499566
Open AccessBiological function identification of phage holin Hol-4086 and treatment of Staphylococcus aureus infection
The treatment of infections caused by drug-resistant Staphylococcus aureus has become increasingly difficult. In this study, the complete genome of phage 4086-1 against S. aureus was sequenced and shown to be 17,960 bp in size, with a GC content of 29.14%. Phylogenetic analysis demonstrated that phage 4086-1 exhibited a close relationship with the Staphylococcus phages SLPW, JPL-50, and LSA2366. BLAST analysis indicated that ORF12 of phage 4086-1 (termed Hol-4086) shares high identity with other reported phage-associated holins. Hol-4086 consists of 140 amino acids and exhibits high sequence identity with some members of the phage_holin_4_1 superfamily (18–125 amino acids). Hol-4086 was then expressed in Escherichia coli and detected using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting. The results of a spot test demonstrated that Hol-4086 had substantial bacteriostatic effects on the host bacteria. S. aureus cells were exposed to Hol-4086 and observed using transmission electron microscopy and scanning electron microscopy. Bacterial cells treated with Hol-4086 showed ultrastructural and morphological changes. The detection of biofilm activity showed that Hol-4086 effectively inhibited and removed S. aureus biofilms. In vivo, treatment with Hol-4086 significantly reduced the number of bacteria, relieved inflammatory responses, and alleviated pathological changes in the organs of infected mice 48 h after treatment. These results demonstrate that Hol-4086 exhibits promising antibacterial potential as an alternative therapy for the treatment of infections caused by S. aureus.
- Open Access
- 25 February 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (3) , 199
Inhibitory Effects of Bovine Lactoferricin-Lactoferrampin on Senecavirus A and Foot-and-Mouth Disease Virus with Recombinant Lactobacillus Oral Treatment in Mice
Foot-and-mouth disease virus (FMDV) and Senecavirus A (SVA) have similar pathogenic characteristics, and both are important pathogens that harm the livestock industry. Studies have shown that lactoferrin peptides can inhibit the replication of various viruses and enhance the body’s immune functions. Based on this, in the present study, we aimed to investigate the effects of bovine lactoferricin-lactoferrampin (LFCA) on replicating FMDV and SVA and to analyze its role in the cellular antioxidant response caused by viral infection; in addition, we fed mice with constructed recombinant Lactobacillus reuteri expressing LFCA. Treatment with LFCA at different stages significantly inhibited the replication of both SVA and FMDV. Pretreatment before SVA infection achieved an inhibition rate of up to 94.9%, while treatment during the FMDV replication stage achieved an inhibition rate of 74.3%. After infection with either virus, intracellular ROS and MDA levels were significantly reduced, as was GSH-Px activity. However, SOD activity showed no significant difference, compared with the virus-exposed group, and remained at a high level, suggesting an increased cellular antioxidant capacity. LFCA treatment significantly increased the transcription levels of the Nrf2, Ho-1, and Nqo1 genes. In mouse experiments, the LFCA-treated group showed significantly lower viral loads in lung and intestinal tissues, compared with the SVA infection group, validating LFCA’s protective effect against SVA infection. These findings demonstrate the potential of LFCA as an antiviral drug.
- 25 February 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (3) , 199
Open AccessInhibitory Effects of Bovine Lactoferricin-Lactoferrampin on Senecavirus A and Foot-and-Mouth Disease Virus with Recombinant Lactobacillus Oral Treatment in Mice
Foot-and-mouth disease virus (FMDV) and Senecavirus A (SVA) have similar pathogenic characteristics, and both are important pathogens that harm the livestock industry. Studies have shown that lactoferrin peptides can inhibit the replication of various viruses and enhance the body’s immune functions. Based on this, in the present study, we aimed to investigate the effects of bovine lactoferricin-lactoferrampin (LFCA) on replicating FMDV and SVA and to analyze its role in the cellular antioxidant response caused by viral infection; in addition, we fed mice with constructed recombinant Lactobacillus reuteri expressing LFCA. Treatment with LFCA at different stages significantly inhibited the replication of both SVA and FMDV. Pretreatment before SVA infection achieved an inhibition rate of up to 94.9%, while treatment during the FMDV replication stage achieved an inhibition rate of 74.3%. After infection with either virus, intracellular ROS and MDA levels were significantly reduced, as was GSH-Px activity. However, SOD activity showed no significant difference, compared with the virus-exposed group, and remained at a high level, suggesting an increased cellular antioxidant capacity. LFCA treatment significantly increased the transcription levels of the Nrf2, Ho-1, and Nqo1 genes. In mouse experiments, the LFCA-treated group showed significantly lower viral loads in lung and intestinal tissues, compared with the SVA infection group, validating LFCA’s protective effect against SVA infection. These findings demonstrate the potential of LFCA as an antiviral drug.